Thirtyfivebio
Develops GPR35-inhibiting drug candidates that protect gut epithelial cells in ulcerative colitis patients
Highlights
- New on EvolcAdded 2026-11-11
About Thirtyfivebio
ThirtyFiveBio is developing a gut epithelial shield for patients with ulcerative colitis, based on GPR35 inhibition that protects gut epithelial cells from inflammatory factors. Its lead programme has three compound series under patent protection, and a preclinical development candidate has been named. First-in-human studies are planned for the first half of 2027.
The company targets ulcerative colitis patients, many of whom do not respond to current anti-inflammatory medicines or relapse after response. Its seed round of $20M was led by Canaan Partners, and AbbVie Ventures has invested alongside it.
ThirtyFiveBio was founded in 2021 and has its registered address in Milton, Abingdon, UK. It was founded by a team of drug discovery experts and entrepreneurs, and co-founder Tom McCarthy serves as Executive Chair. The company is part of the Molecule to Medicine (MTM) ecosystem and is raising a syndicated Series A to progress to the clinic.
Product: Preclinical GPR35 antagonist drug candidates for ulcerative colitis, designed to protect gut epithelium.
Jobs at Thirtyfivebio
Leadership
- Kirsty McCarthy · Co-founder & CEO of MTMSource: company website
- Peter Joyce · Co-founder & CEO of Greywolf TherapeuticsSource: company website
- Stuart Hughes · Co-founder & CEO of Nuage TherapeuticsSource: company website
- Tom McCarthy · Co-founder & Executive ChairSource: company website
- James Westcott · CEOSource: company website
- Helen Carlile · Director of OperationsSource: company website
More biotech & pharma companies
Thornton & Ross
Consumer healthcare and generic medicines for UK patients and households, part of the STADA GroupTithonia Group
Specialty pharma group that runs a medicine licensing and distribution platform and product brands for prescribers and patients in EuropeTitian Software
Sample management software for life science labs, including pharma, biotech, CROs and biobanksRemote-friendlyTiziana Life Sciences
Clinical-stage biotech developing intranasal immunotherapies for multiple sclerosis, Alzheimer's and ALSTMC Pharma Services
Outsourced drug development services for small and mid-sized biotech and pharma firms, from early clinical trials to EU and UK market accessTorrent Pharma (UK)
Distributes generic prescription medicines to UK pharmacies, wholesalers and hospitalsRemote-friendly
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Google Analytics 4Medium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Integration code on pageinline script loader
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Content management
- WebflowHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Forms
- Google reCAPTCHAHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- AWSHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.